Alpha Teknova, Inc. (TKNO) · Nov 4, 2026 · Earnings

Alpha Teknova earnings beat as revenue guidance rises on biotech demand

Beat — Revenue $12.7M vs ~$11.8M consensus; FY26 guide $46–48M from $45–47M

Alpha Teknova earnings show stronger biotech-driven demand, a revenue beat and higher 2026 guidance, alongside ongoing losses and fresh equity dilution.

Teknova is a life-sciences reagent supplier trying to convert a recovering biotech funding environment into sustained custom-product growth, while still operating below profitability. Its prior quarter had already shown improving demand and lifted 2026 revenue guidance to $45–47 million, so the direction of travel was known before this release.

The quarter beat the market’s top-line bar and improved execution. Revenue reached $12.7 million, about 8% above published estimates clustered around $11.7–$11.8 million, while EPS of negative $0.06 was roughly in line with consensus. Clinical Solutions was the standout, growing 86%, while the larger Lab Essentials business grew 9%, giving the result a healthier mix than a single customer or segment spike.

Q3 2026Q3 2025Consensus / prior guide
Revenue (Financial Results)$12.7M (+22%)$10.5M~$11.8M
Gross margin (Financial Results)38.0%30.7%
Net loss (Financial Results)$(3.5)M$(4.3)M
Adjusted EBITDA (Financial Results)$(1.0)M$(1.6)M
Free Cash Outflow (Non-GAAP reconciliation)$(1.4)M$(2.4)M
FY26 revenue outlook (2026 Outlook)$46–48M$45–47M prior guide

The guidance raise confirms the improvement is carrying into the full year. Teknova lifted its 2026 revenue range by $1 million at both ends and held full-year Free Cash Outflow below $8 million, despite remaining loss-making. 〔0〕 The important distinction is that this is an execution and demand signal, not yet a profitability inflection: Adjusted EBITDA remained negative and operating expenses rose as the company invested in sales and marketing.

The balance sheet is safer, but the solution came with meaningful dilution. The October offering generated approximately $42.9 million of net proceeds through the issuance of 9.2 million shares, materially extending financial flexibility relative to the $16.6 million of cash and short-term investments held at quarter-end. That funding reduces near-term balance-sheet pressure, but it does not by itself prove the operating model can reach break-even.

Bottom line: This is a modestly better quarter than expected and the higher revenue outlook strengthens Teknova’s recovery story. The result advances demand and execution, but ongoing cash losses and the newly issued equity keep it from being a full business-model breakthrough.

Original filing on SEC EDGAR

Alpha Teknova earnings beat as revenue guidance rises on biotech demand | TKNO Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.